Mobile Menu
Deals & Transactions

Conyers advises Horizon Pharma plc on issue of $400 Million 2.50% Exchangeable Senior Notes

March 2015 David J. Doyle

Conyers provided Bermuda law advice in connection with the issue by Horizon Pharma Investment Limited, a Bermuda exempted company and a wholly-owned subsidiary of Horizon Pharma plc, of its offering of $400 million aggregate principal amount of Exchangeable Senior Notes due 2022 in a private placement to qualified institutional buyers pursuant to Rule 144A under the United States Securities Act of 1933 which closed on March 13, 2015.

Horizon Pharma plc (NASDAQ: HZNP), is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs.

The notes are the general unsecured senior obligations of Horizon Pharma Investment Limited and accrue interest at an annual rate of 2.50% payable semiannually. The notes will mature on March 15, 2022, unless earlier exchanged, repurchased or redeemed and the notes are fully and unconditionally guaranteed on a senior unsecured basis by Horizon Pharma plc.

David J. Doyle advised on the matter working alongside Cooley LLP and McCann Fitzgerald.

March 16, 2015

 


David J. Doyle
Director

BERMUDA   +1 441 299 4902


Accolades
_

"Few firms can come close to Conyers on one critical metric, and this is the breadth of the client base."
- IFLR1000

expertise

Corporate


Related Jurisdictions

Bermuda


Related International Markets

Bermuda


Media Contact

For media enquiries, please contact media@conyersdill.com

Deals & Transactions

Conyers advises Horizon Pharma plc on issue of $400 Million 2.50% Exchangeable Senior Notes

17 March 2015 David J. Doyle

Conyers provided Bermuda law advice in connection with the issue by Horizon Pharma Investment Limited, a Bermuda exempted company and a wholly-owned subsidiary of Horizon Pharma plc, of its offering of $400 million aggregate principal amount of Exchangeable Senior Notes due 2022 in a private placement to qualified institutional buyers pursuant to Rule 144A under the United States Securities Act of 1933 which closed on March 13, 2015.

Horizon Pharma plc (NASDAQ: HZNP), is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs.

The notes are the general unsecured senior obligations of Horizon Pharma Investment Limited and accrue interest at an annual rate of 2.50% payable semiannually. The notes will mature on March 15, 2022, unless earlier exchanged, repurchased or redeemed and the notes are fully and unconditionally guaranteed on a senior unsecured basis by Horizon Pharma plc.

David J. Doyle advised on the matter working alongside Cooley LLP and McCann Fitzgerald.

March 16, 2015

 


David J. Doyle
Director

BERMUDA   +1 441 299 4902


 

expertise

Corporate


JURISDICTION(S)

Bermuda


International Office(s)

Bermuda